MCM
INSY

Matarin Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Matarin Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-20,796
Closed -$592K – 242
2015
Q3 		$592K Buy
+20,796
New +$765K 0.12% 171

Other funds holding INSY

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
GAM
Gotham Asset Management New York $32.7B AUM 27.65% 1-Year Est. Return

Matarin Capital Management's INSY Position: Q4 2015 in Review

Matarin Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q4 2015, closing a stake of 20,796 shares — an estimated $592K sold.

Matarin Capital Management first reported a position in INSY in Q3 2015 and held it in 1 quarter. The position peaked at $592K in Q3 2015. 154 funds tracked by Wall St. Rank hold INSY as of Q4 2015.

  • Matarin Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q4 2015 after selling out during the quarter.
  • Matarin Capital Management sold 20,796 Insys Therapeutics, Inc. shares in Q4 2015, an estimated $592K.
  • Matarin Capital Management first reported a position in Insys Therapeutics, Inc. in Q3 2015 and held it in 1 quarter.
  • Matarin Capital Management's Insys Therapeutics, Inc. position peaked at $592K in Q3 2015.
  • 154 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q4 2015.

Based on Matarin Capital Management's 13F filing for Q4 2015, filed 10 Feb 2016.